H. Kim Lyerly, MD
George Barth Geller Professor of Cancer Research
Departments / Divisions- Surgery / Surgical Oncology
- Pathology / Pathology - General
- Immunology
Address
DUMC 2606
Durham, NC 27710
Appointment Telephone
919-668-6688
Office Telephone
919-681-8350
Fax Telephone
919-681-7970
- MD, University of California, Los Angeles, David Geffen School of Medicine, 1983
- Surgery, Duke University Medical Center, 1984-1985, 1987-1990
- Research, Duke University Medical Center, 1985-1987
Clinical Interests
Surgical treatment of breast cancer; gene- and immune-based therapy for breast, kidney, lung, colon, and pancreatic cancers
This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Advoset
- AlphaVax, Inc.
- Argos Therapeutics, Inc.
- Biologic Response Laboratories
- Etubics
- VentiRx Pharmaceuticals
- mAbRx, Inc
Representative Publications
Lyerly HK. Quantitating cellular immune responses to cancer vaccines. Semin Oncol. 2003 Jun;30(3 Suppl 8):9-16.
(2003)
Abstract
Morse MA, Clay TM, Colling K, Hobeika A, Grabstein K, Cheever MA, Lyerly HK. HER2 Dendritic Cell Vaccines. Clin Breast Cancer. 2003 Feb;3 Suppl 4:S164-72.
(2003)
Abstract
Morse MA, Nair SK, Mosca PJ, Hobeika AC, Clay TM, Deng Y, Boczkowski D, Proia A, Neidzwiecki D, Clavien PA, Hurwitz HI, Schlom J, Gilboa E, Lyerly HK. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest. 2003 Jun;21(3):341-9.
(2003)
Abstract
Clay TM, Morse M, Lyerly HK. Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes. Expert Opin Biol Ther. 2002 Apr;2(4):353-60.
(2002)
Abstract
Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother. 2002 Mar-Apr;25(2):97-138.
(2002)
Abstract
Morse MA, Clay TM, Lyerly HK. Current status of adoptive immunotherapy of malignancies. Expert Opin Biol Ther. 2002 Mar;2(3):237-47.
(2002)
Abstract
Morse MA, Lyerly HK. DNA and RNA modified dendritic cell vaccines. World J Surg. 2002 Jul;26(7):819-25.
(2002)
Abstract
Morse MA, Nair SK, Boczkowski D, Tyler D, Hurwitz HI, Proia A, Clay TM, Schlom J, Gilboa E, Lyerly HK. The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer. 2002;32(1):1-6.
(2002)
Abstract
Morse MA, Rizzieri D, Stenzel TT, Hobeika AC, Vredenburgh JJ, Chao NJ, Clay TM, Mosca PJ, Lyerly HK. Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants. J Hematother Stem Cell Res. 2002 Aug;11(4):659-68.
(2002)
Abstract
Mosca PJ, Hobeika AC, Colling K, Clay TM, Thomas EK, Caron D, Lyerly HK, Morse MA. Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. J Leukoc Biol. 2002 Sep;72(3):546-53.
(2002)
Abstract
Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 2000 Feb 15;60(4):1028-34.
(2000)
Abstract
Li Y, Bendandi M, Deng Y, Dunbar C, Munshi N, Jagannath S, Kwak LW, Lyerly HK. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood. 2000 Oct 15;96(8):2828-33.
(2000)
Abstract
Lyerly HK, Clay T, Morse MA. Optimizing dendritic cell function by genetic modification. J Natl Cancer Inst. 2000 Aug 2;92(15):1198-9.
(2000)
Abstract
Markert ML, Hicks CB, Bartlett JA, Harmon JL, Hale LP, Greenberg ML, Ferrari G, Ottinger J, Boeck A, Kloster AL, McLaughlin TM, Bleich KB, Ungerleider RM, Lyerly HK, Wilkinson WE, Rousseau FS, Heath-Chiozzi ME, Leonard JM, Haase AT, Shaw GM, Bucy RP, Douek DC, Koup RA, Haynes BF, Bolognesi DP, Weinhold KJ. Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection. AIDS Res Hum Retroviruses. 2000 Mar 20;16(5):403-13.
(2000)
Abstract
Morse MA, Nair S, Fernandez-Casal M, Deng Y, St Peter M, Williams R, Hobeika A, Mosca P, Clay T, Cumming RI, Fisher E, Clavien P, Proia AD, Niedzwiecki D, Caron D, Lyerly HK. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J Clin Oncol. 2000 Dec 1;18(23):3883-93.
(2000)
Abstract
Mosca PJ, Hobeika AC, Clay TM, Nair SK, Thomas EK, Morse MA, Lyerly HK. A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood. 2000 Nov 15;96(10):3499-504.
(2000)
Abstract
Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 1999 Jan 1;59(1):56-8.
(1999)
Abstract
Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res. 1999 Jun;5(6):1331-8.
(1999)
Abstract
Morse MA, Lyerly HK, Li Y. The role of IL-13 in the generation of dendritic cells in vitro. J Immunother. 1999 Nov;22(6):506-13.
(1999)
Abstract
Morse MA, Vredenburgh JJ, Lyerly HK. A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy. J Hematother Stem Cell Res. 1999 Dec;8(6):577-84.
(1999)
Abstract
Nair SK, Hull S, Coleman D, Gilboa E, Lyerly HK, Morse MA. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer. 1999 Jul 2;82(1):121-4.
(1999)
Abstract
Morse MA, Lyerly HK, Gilboa E, Thomas E, Nair SK. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res. 1998 Jul 15;58(14):2965-8.
(1998)
Abstract
Morse MA, Zhou LJ, Tedder TF, Lyerly HK, Smith C. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy. Ann Surg. 1997 Jul;226(1):6-16.
(1997)
Abstract
